share_log

Benchmark Reiterates Speculative Buy on ImmunoPrecise Antibodies, Maintains $7 Price Target

Benzinga ·  Jul 11, 2023 20:09

Benchmark analyst Robert Wasserman reiterates ImmunoPrecise Antibodies (NASDAQ:IPA) with a Speculative Buy and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment